BenzingaOctober 19, 2026 at 8:23 AM NY8 Days Ago

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

REGNRegeneron Pharmaceuticals, Inc.

Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.

What This Story Means

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga